Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 29, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 29, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/29/16 - "Solid Pharmaceutical Dosage Form for Release of at Least One Active Pharmaceutical Ingredient in the Oral Cavity" in Patent Application Approval...
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Hugerth, Andreas; Lindell, Katarina; Nicklasson, Fredrik; Thyresson, Kristina, filed on June 2, 2014, was made available online on April 14, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application
4/29/16 - AbbVie Announces Real-World Data with VIEKIRAX ombitasvir/paritaprevir/ritonavir tablets and EXVIERA dasabuvir tablets from Large German Hepatitis...
By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced new real-world data showing 96 percent of genotype 1 patients and 100 percent of genotype 4 patients achieved sustained virologic response at 12 weeks post-treatment. "Real-world studies complement randomized controlled trials and help to furt
4/29/16 - AbbVie buys cancer drug firm for $5.8 billion [Chicago Tribune]
AbbVie CEO Richard Gonzalez told investors on an earnings call Thursday morning that the incentives are critical to ensure AbbVie can retain Stemcentrx staff who have five experimental drugs in human trials, including a drug called Rova-T, which could be on the market as soon as 2018.. If approved, the cancer drugs would help AbbVie cope with growi
4/29/16 - AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous...
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals. By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced that 91 percent of genotype 1 chronic hepatitis C virus in
4/29/16 - ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
Dr Edwin Moses, CEO of Ablynx, commented: "We are very pleased that Novartis will soon begin clinical development of this novel Nanobody against a GPCR. About the collaboration between Novartis and Ablynx. In December 2005, Ablynx and Novartis entered into an agreement to discover and develop novel Nanobody-based therapeutics against a number of di
4/29/16 - Allergan Reinforces Commitment to Anti-Infective Innovation with 20 Abstracts Highlighted at ECCMID 2016
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global pharmaceutical company committed to developing new treatment options for infectious diseases, announced that new data from its anti-infective portfolio will be featured in 20 abstracts during the upcoming European Congress of Clinical Microbiology and Infectious...
4/29/16 - An Application for the Trademark "SHARE SOLUTIONS SUPPORT. KNOWLEDGE. ANSWERS." Has Been Filed by Teva Pharmaceuticals USA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SHARE SOLUTIONS SUPPORT. by Herschel Perel, representing Teva Pharmaceuticals USA. This application was made available to the public on April 08, 2016.
4/29/16 - Arbutus Biopharma Corp. Files SEC Form DEF 14A, Other Definitive Proxy Statements (Apr. 8, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on April 7, 2016. The SEC file number is 0001628280-16-014088.. A U.S. Securities and Exchange Commission filing is a formal
4/29/16 - Arbutus Biopharma Corp. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material (Apr. 8, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on April 7, 2016. The SEC file number is 0001628280-16-014091.. A U.S. Securities and Exchange Commission filing is a formal
4/29/16 - Azurrx Biopharma, Inc. Files SEC Form D, Notice of Exempt Offering of Securities (Apr. 11, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Azurrx Biopharma, Inc. was posted on April 11, 2016. The SEC file number is 0001415889-16-005478.. A U.S. Securities and Exchange Commission filing is a formal
4/29/16 - BioNumerik Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., April 29 BioNumerik Pharmaceuticals, San Antonio, has been assigned a patent developed by Frederick H. Hausheer, Boerne, Texas, for "compositions and methods of use of compounds to increase cancer patient survival time." The patent application was filed on July 15, 2008. Written by Kusum Sangma; edited by Jaya Anand.
4/29/16 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Apr. 6, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on April 6, 2016. The SEC file number is 0001213900-16-012284.. A U.S. Securities and Exchange Commission filing is a formal
4/29/16 - CorMedix Inc. to Present Post-Market Clinical Utility Data from Neutrolin Usage Monitoring Program on May 23, 2016
By a News Reporter-Staff News Editor at Drug Week CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that Dr. Christoph Wanner, Professor of Medicine and Director of Nephrology at the University of Wurzburg, wi
4/29/16 - CPhI, the Leading International Pharmaceutical Event Series, to Launch New North American Edition in May 2017
By a News Reporter-Staff News Editor at Drug Week CPhI, the leading international pharmaceutical business and networking event, is pleased to announce the latest addition to its global events portfolio, CPhI North America. CPhl North America will take place May 16-18, 2017 at the Pennsylvania Convention Center in Philadelphia, PA alongside Inform
4/29/16 - Current & Future Trends in Pharmaceutical Big Data Across Commercial Functions
By a News Reporter-Staff News Editor at Drug Week Big Data has the potential to generate valuable insights for key commercial decisions within the biopharmaceutical industry. Big Data/Real World Analytics can be the catalyst for dramatic change in U.S. healthcare if adopted properly. The related report, "Big Data in Pharma: Current& Future Trends
4/29/16 - Data on One-Carbon Group Transferases Reported by Researchers at University of Toronto (A Potent, Selective, and Cell-Active Inhibitor of Human Type...
Data on One-Carbon Group Transferases Reported by Researchers at University of Toronto. By a News Reporter-Staff News Editor at Health& Medicine Week Fresh data on Enzymes and Coenzymes are presented in a new report. The news reporters obtained a quote from the research from the University of Toronto, "Consequently, selective small-molecule inhib
4/29/16 - Data on Pharmacoeconomics Reported by Researchers at Monash University (What Can We Expect from Value-Based Funding of Medicines? A Retrospective...
Data on Pharmacoeconomics Reported by Researchers at Monash University. According to news reporting from Clayton, Australia, by VerticalNews journalists, research stated, "Deciding on public funding for pharmaceuticals on the basis of value for money is now widespread. The news correspondents obtained a quote from the research from Monash Universit
4/29/16 - FDA Advisory Committee Votes Against Approval of Eteplirsen; Coalition Duchenne Comments
Coalition Duchenne, a Newport Beach, California based charity committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. Food and Drug Administration advisory committee hearing on the efficacy of the Sarepta Therapeutic's novel Duchenne drug eteplirsen. The meeting at the Mar
4/29/16 - Findings from North Dakota State University in the Area of Drug Delivery Systems Reported (The Potential of Silk and Silk-Like Proteins as Natural...
Findings from North Dakota State University in the Area of Drug Delivery Systems Reported. By a News Reporter-Staff News Editor at Drug Week A new study on Drugs and Therapies is now available. The news reporters obtained a quote from the research from North Dakota State University, "Thus, the pharmaceutical industry has an interest in drug deliv
4/29/16 - Galena Biopharma, Inc. Files SEC Form 8-K, Current Report (Apr. 7, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Galena Biopharma, Inc. was posted on April 7, 2016. The SEC file number is 0001390478-16-000092.. A U.S. Securities and Exchange Commission filing is a formal d
4/29/16 - Germany : How glass packages medications safely [TendersInfo (India)]
They are small, extremely small. And sometimes even barely visible. The innovation called SCHOTT Vials Delamination Controlled is being received very positively and is now more and more being qualified within the pharmaceutical industry in the US and in Europe.
4/29/16 - Germany,Thailand : Werum IT Solutions expands Asia Pacific presence with acquisition [TendersInfo (India)]
The world leading provider of Manufacturing Execution Systems software for the pharmaceutical and biopharmaceutical industry, Werum IT Solutions GmbH, and Factorytalk Co., Ltd., Thailand, a major consulting company for pharma producers in Southeast Asia,. All existing Factorytalk MES employees many of whom are long-term experienced MES specialists
4/29/16 - Hemispherx Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Apr. 6, 2016)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Hemispherx Biopharma Inc. was posted on April 6, 2016. The SEC file number is 0001613377-16-000005.. A U.S. Securities and Exchange Commission filing is a forma
4/29/16 - Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab
By a News Reporter-Staff News Editor at Drug Week Leica Biosystems and Merrimack Pharmaceuticals announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell...
4/29/16 - Lupin launches five brands in US with introduction of Methergine [Asian News International]
New Delhi, Apr. 29: Pharmaceutical company Lupin Ltd. is bolstering its US branded drugs portfolio with the introduction of Methergine, an oral tablet used to treat postpartum haemorrhage, in the US market. With the US being Lupin's largest market, the company earned USD 2.06 billion revenue in fiscal year 2015, which garnered 45 percent to the com
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415